Recent findings indicate that semaglutide, a GLP-1 medication, may not only assist with weight management but could also slow aging in mice.
Semaglutide, the active component in GLP-1 medications like Ozempic and Wegovy, appears to extend beyond merely regulating appetite and blood sugar levels. A study funded by the National Institutes of Health (NIH) demonstrates that this drug can mitigate numerous detrimental effects linked to aging while prolonging lifespan in older, healthy mice.
A team from the University of California, Berkeley, conducted a comparative analysis of semaglutide against calorie restriction, widely recognized as a prime method to enhance longevity in laboratory animals. The drug mimicked several anti-aging benefits associated with reduced caloric intake, but interestingly, it surpassed calorie restriction in noteworthy ways.
This research opens the door to a fascinating possibility: GLP-1 drugs may affect the aging process directly. Prior studies have indicated that these medications can postpone the onset of various age-related conditions. If semaglutide interacts with the biological pathways that drive aging, it could clarify the extensive health benefits observed with GLP-1 treatments.
Rafael de Cabo, Ph.D., a senior investigator at the NIH’s National Institute on Aging (NIA), emphasized the connection, stating, “Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see.”
To examine the drug's effects on aging, the research team led by Danica Chen, Ph.D., administered semaglutide to 20-month-old female mice over three months. Compared to those not receiving the drug, the treated mice exhibited stronger muscle and cognitive functions. Gene activity analyses indicated significant improvements in several aging-related biological markers, such as reduced inflammation and enhanced tissue repair capabilities.
The results regarding lifespan were particularly noteworthy. Another group of mice treated with semaglutide until their demise demonstrated a median lifespan approximately 100 days longer than their untreated counterparts.
Considering that semaglutide lowers appetite, researchers were curious whether the apparent anti-aging impact was merely a result of calorie reduction. To assess this, they conducted a five-month trial where one group of 20-month-old female mice received semaglutide, while a second group followed a 24% calorie-restricted diet to align with the consumption of the treated mice.
The findings revealed that both strategies produced comparable effects, with stable physiological measurements across the board. However, semaglutide outperformed calorie restriction in certain areas.
Mice on the drug demonstrated improvements above their initial levels in areas such as exploratory behaviors, spatial memory, and blood sugar management. Their metabolic rates remained relatively unchanged, unlike the calorie-restricted group, which experienced a metabolic slowdown.
These observations suggest that semaglutide might be activating biological pathways distinct from those associated with calorie restriction. “These differences indicate the potential for GLP-1 drugs to engage in a biological process beyond calorie reduction,” stated Chen, who is the corresponding author and professor of metabolic biology and nutrition at UC Berkeley. “Identifying these pathways and understanding their benefits will be pivotal for future longevity-enhancing research.”
While this research could pave the way for novel insights in longevity, it does not imply that Ozempic, Wegovy, or other GLP-1 medications can directly extend human lifespan. Ongoing clinical research will be essential to establish whether the effects observed in mice can also be expected in humans. One such exploration includes a recent post-hoc analysis of the SLIM LIVER trial, although further studies are warranted to determine any significant impacts of GLP-1 medications on human aging or lifespan.
Chen noted that future clinical studies may also focus on healthy older adults. Should researchers observe similar advantages in individuals without obesity or diabetes, the potential applications of GLP-1 treatments could significantly expand.
This research was supported by NIH grants R01AG063404, R01AG063389, and R01AG082105.
Materials provided by NIH/Office of the Director. Content may be edited for style and length.
This Strange New Magnetism Could Change How Computers Work
Scientists Decode a 12,000-Year-Old Mystery Hidden in Ancient Spear Points
Switzerland’s Glaciers Lost More Than 5% of Their Ice in Just One Year
Scientists Tested This Tropical Fruit for Diabetes – and Found an Unexpected Blood Pressure Effect
Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:
Keep up to date with the latest news from ScienceDaily via social networks:
Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Discussion
Sign in to join the discussion.